Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Farmers Insurance
McKesson
Fish and Richardson
Daiichi Sankyo
Baxter
Express Scripts
Johnson and Johnson
Colorcon
Julphar

Generated: December 11, 2017

DrugPatentWatch Database Preview

Fluoxetine hydrochloride; olanzapine - Generic Drug Details

« Back to Dashboard

What are the generic sources for fluoxetine hydrochloride; olanzapine and what is the scope of fluoxetine hydrochloride; olanzapine freedom to operate?

Fluoxetine hydrochloride; olanzapine
is the generic ingredient in two branded drugs marketed by Par Pharm, Sandoz, Teva Pharms, and Lilly, and is included in five NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fluoxetine hydrochloride; olanzapine has forty-seven patent family members in twenty-five countries.

There are twenty-seven drug master file entries for fluoxetine hydrochloride; olanzapine. Five suppliers are listed for this compound.

Summary for fluoxetine hydrochloride; olanzapine

Pharmacology for fluoxetine hydrochloride; olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-002Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-001Apr 9, 2007ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmOLANZAPINE AND FLUOXETINE HYDROCHLORIDEfluoxetine hydrochloride; olanzapineCAPSULE;ORAL077742-001Nov 2, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
SandozOLANZAPINE AND FLUOXETINE HYDROCHLORIDEfluoxetine hydrochloride; olanzapineCAPSULE;ORAL078901-004Nov 16, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-005Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYY► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fluoxetine hydrochloride; olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-002Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-005Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-001Apr 9, 2007► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-002Dec 24, 2003► Subscribe► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-005Dec 24, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluoxetine hydrochloride; olanzapine

Country Document Number Estimated Expiration
New Zealand332039► Subscribe
Japan2002516282► Subscribe
Hong Kong1040055► Subscribe
Brazil9911049► Subscribe
Canada2250187► Subscribe
Israel139592► Subscribe
European Patent Office0921802► Subscribe
Australia4008699► Subscribe
Hungary0101901► Subscribe
Canada2332814► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Mallinckrodt
Argus Health
UBS
Baxter
Fuji
Teva
QuintilesIMS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot